Arsanis Inc (NASDAQ:ASNS) shares were up 9.8% during trading on Monday . The company traded as high as $2.74 and last traded at $2.02. Approximately 4,600 shares were traded during mid-day trading, a decline of 96% from the average daily volume of 114,169 shares. The stock had previously closed at $1.84.
A number of research analysts recently commented on ASNS shares. Cantor Fitzgerald restated a “buy” rating and issued a $26.00 price target on shares of Arsanis in a research report on Thursday, June 28th. Zacks Investment Research upgraded Arsanis from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a research report on Tuesday, July 10th. Cowen cut Arsanis from an “outperform” rating to a “market perform” rating in a research report on Monday, July 2nd. Piper Jaffray Companies decreased their target price on Arsanis to $2.50 and set a “neutral” rating on the stock in a research report on Monday, August 13th. Finally, Citigroup cut Arsanis from a “buy” rating to a “neutral” rating in a research report on Monday, July 9th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $14.88.
The company has a debt-to-equity ratio of 0.20, a current ratio of 5.54 and a quick ratio of 5.54. The stock has a market cap of $23.19 million and a PE ratio of -0.12.
Arsanis (NASDAQ:ASNS) last released its earnings results on Monday, August 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.82) by ($0.03). As a group, equities analysts expect that Arsanis Inc will post -3.12 earnings per share for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in ASNS. Schwab Charles Investment Management Inc. bought a new position in Arsanis in the first quarter valued at about $200,000. Northern Trust Corp bought a new position in Arsanis in the first quarter valued at about $735,000. BlackRock Inc. bought a new position in Arsanis in the first quarter valued at about $4,029,000. JPMorgan Chase & Co. grew its position in Arsanis by 6.4% in the first quarter. JPMorgan Chase & Co. now owns 247,415 shares of the company’s stock valued at $5,663,000 after acquiring an additional 14,819 shares during the last quarter. Finally, New York State Common Retirement Fund acquired a new stake in shares of Arsanis during the first quarter valued at about $114,000. Hedge funds and other institutional investors own 68.70% of the company’s stock.
About Arsanis (NASDAQ:ASNS)
Arsanis, Inc, a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients.
Featured Article: Conference Calls and Individual Investors